VRCA Relative Valuation
VRCA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VRCA is overvalued; if below, it's undervalued.
Historical Valuation
Verrica Pharmaceuticals Inc (VRCA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.25. The fair price of Verrica Pharmaceuticals Inc (VRCA) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：7.60
Fair
-4.00
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Verrica Pharmaceuticals Inc. (VRCA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -2.97. The thresholds are as follows: Strongly Undervalued below -8.39, Undervalued between -8.39 and -5.68, Fairly Valued between -0.26 and -5.68, Overvalued between -0.26 and 2.45, and Strongly Overvalued above 2.45. The current Forward EV/EBITDA of 0.00 falls within the Overvalued range.
-3.25
EV/EBIT
Verrica Pharmaceuticals Inc. (VRCA) has a current EV/EBIT of -3.25. The 5-year average EV/EBIT is -3.97. The thresholds are as follows: Strongly Undervalued below -8.25, Undervalued between -8.25 and -6.11, Fairly Valued between -1.83 and -6.11, Overvalued between -1.83 and 0.31, and Strongly Overvalued above 0.31. The current Forward EV/EBIT of -3.25 falls within the Historic Trend Line -Fairly Valued range.
2.76
PS
Verrica Pharmaceuticals Inc. (VRCA) has a current PS of 2.76. The 5-year average PS is 32.11. The thresholds are as follows: Strongly Undervalued below -44.48, Undervalued between -44.48 and -6.18, Fairly Valued between 70.41 and -6.18, Overvalued between 70.41 and 108.70, and Strongly Overvalued above 108.70. The current Forward PS of 2.76 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Verrica Pharmaceuticals Inc. (VRCA) has a current P/OCF of 0.00. The 5-year average P/OCF is -3.69. The thresholds are as follows: Strongly Undervalued below -10.80, Undervalued between -10.80 and -7.24, Fairly Valued between -0.14 and -7.24, Overvalued between -0.14 and 3.42, and Strongly Overvalued above 3.42. The current Forward P/OCF of 0.00 falls within the Overvalued range.
-2.80
P/FCF
Verrica Pharmaceuticals Inc. (VRCA) has a current P/FCF of -2.80. The 5-year average P/FCF is -3.80. The thresholds are as follows: Strongly Undervalued below -7.72, Undervalued between -7.72 and -5.76, Fairly Valued between -1.84 and -5.76, Overvalued between -1.84 and 0.12, and Strongly Overvalued above 0.12. The current Forward P/FCF of -2.80 falls within the Historic Trend Line -Fairly Valued range.
Verrica Pharmaceuticals Inc (VRCA) has a current Price-to-Book (P/B) ratio of -4.17. Compared to its 3-year average P/B ratio of 18.54 , the current P/B ratio is approximately -122.47% higher. Relative to its 5-year average P/B ratio of 13.66, the current P/B ratio is about -130.50% higher. Verrica Pharmaceuticals Inc (VRCA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -48.34%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -34.81% , the current FCF yield is about -100.00% lower.
-4.69
P/B
Median3y
18.54
Median5y
13.66
-40.99
FCF Yield
Median3y
-48.34
Median5y
-34.81
Competitors Valuation Multiple
The average P/S ratio for VRCA's competitors is 0.00, providing a benchmark for relative valuation. Verrica Pharmaceuticals Inc Corp (VRCA) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -905.39%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of VRCA increased by 20.29% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -0.25 to -2.85.
The secondary factor is the Margin Expansion, contributed -99.77%to the performance.
Overall, the performance of VRCA in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Verrica Pharmaceuticals Inc (VRCA) currently overvalued or undervalued?
What is Verrica Pharmaceuticals Inc (VRCA) fair value?
How does VRCA's valuation metrics compare to the industry average?
What is the current P/B ratio for Verrica Pharmaceuticals Inc (VRCA) as of Dec 05 2025?
What is the current FCF Yield for Verrica Pharmaceuticals Inc (VRCA) as of Dec 05 2025?
What is the current Forward P/E ratio for Verrica Pharmaceuticals Inc (VRCA) as of Dec 05 2025?